Sivik Global Healthcare’s Sarepta Therapeutics SRPT Stock Holding History

Sivik Global Healthcare’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$1.05M	–	43
2024 Q4	$1.22M	Buy	+10,000	New	+$1.23M	0.64%	37
2023 Q3	–	Sell	-811	Closed	-$93K	–	45
2023 Q2	$93K	Sell	811 -12,189	-94%	-$1.57M	0.02%	43
2023 Q1	$1.79M	Buy	+13,000	New	+$1.69M	0.77%	39
2022 Q1	–	Sell	-25,000	Closed	-$2.25M	–	58
2021 Q4	$2.25M	Buy	+25,000	New	+$2.14M	0.96%	40
2021 Q3	–	Sell	-25,000	Closed	-$1.94M	–	55
2021 Q2	$1.94M	Buy	25,000 +5,000	+25%	+$379K	0.38%	46
2021 Q1	$1.49M	Buy	+20,000	New	+$1.85M	0.54%	46
2020 Q1	–	Sell	-22,500	Closed	-$2.9M	–	58
2019 Q4	$2.9M	Buy	22,500 +7,500	+50%	+$757K	1.08%	41
2019 Q3	$1.13M	Sell	15,000 -12,500	-45%	-$1.48M	0.57%	42
2019 Q2	$4.18M	Buy	27,500 +12,500	+83%	+$1.52M	1.01%	29
2019 Q1	$1.79M	Sell	15,000 -5,000	-25%	-$643K	0.66%	51
2018 Q4	$2.18M	Sell	20,000 -5,000	-20%	-$625K	1.18%	37
2018 Q3	$4.04M	Sell	25,000 -5,000	-17%	-$684K	1.44%	34
2018 Q2	$3.96M	Hold	30,000	–	–	1.52%	32
2018 Q1	$2.22M	Hold	30,000	–	–	1.04%	40
2017 Q4	$1.67M	Buy	+30,000	New	+$1.59M	0.62%	61

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sivik Global Healthcare's SRPT Position: Q1 2025 in Review

Sivik Global Healthcare sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 10,000 shares — an estimated $1.05M sold.

Sivik Global Healthcare first reported a position in SRPT in Q4 2017 and held it in 15 quarters. The position peaked at $4.18M in Q2 2019. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Sivik Global Healthcare reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Sivik Global Healthcare sold 10,000 Sarepta Therapeutics shares in Q1 2025, an estimated $1.05M.
Sivik Global Healthcare first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 15 quarters.
Sivik Global Healthcare's Sarepta Therapeutics position peaked at $4.18M in Q2 2019.
431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Sivik Global Healthcare's 13F filing for Q1 2025, filed 22 Apr 2025.